OLGIM stage at index and last surveillance endoscopy
| Tmax | Regression 88 (42%) | Stable 74 (35%) | Progression 49 (23%) | ||||||
| 0 | I | II | III | IV | |||||
| 68 | 45 | 52 | 38 | 8 | |||||
| 0 | 32 | 21 | 7 | 4 | 0 | 0 | – | 66% | 34% |
| I | 56 | 20 | 18 | 12 | 6 | 0 | 36% | 32% | 32% |
| II | 67 | 15 | 14 | 19 | 16 | 3 | 43% | 28% | 28% |
| III | 37 | 10 | 5 | 9 | 12 | 1 | 65% | 32% | 3% |
| IV | 19 | 2 | 1 | 8 | 4 | 4 | 79% | 21% | – |
Grey colour denote the patients who had the same OLGIM stage (0, I, II, III or IV) at both index and last surveillance endoscopy (Tmax). Above the diagonal indicates patients in whom OLGIM stage became higher during follow-up. Under the diagonal indicates patients in whom OLGIM stage became lower during follow-up. Mean follow-up time was 50.8 months (SD 32). Missing n=68, as only patients who underwent at least two surveillance endoscopies during follow-up were included.
OLGIM, operative link on intestinal metaplasia.